As she steps down, a look at the top two contenders -- Vijay Rupani and Nitin Patel -- who could become Gujarat's next chief minister.
Many see Nirma's Lafarge deal as some kind of second coming for the Patels.
Tata Motors ended the year selling 21,012 Nanos, up from 16,901 in FY15.
Now with 13-14 million-tonne capacity, Nirma will emerge as a serious player in India's cement landscape.
Karsanbhai Patel's risk-taking abilities are on display once again.
Droom has seen aircraft such as the Falcon, Hawk and Cessna being rented.
There was buzz of Piyush Goyal being elevated to Cabinet rank but only Prakash Javadekar made the cut.
The traditional Indian desserts market is around Rs 40,000-45,000 crore (Rs 400-450 billion).
The regulator had issued alerts in June and July of 2015.
The percentage of non-standard quality drugs in the state has been in the range of 2-2.5% as compared to an all-India average of 5-6%
Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.
In 2013, Daiichi had launched the arbitration proceedings in Singapore.
Alkem Labs was issued drug alerts twice last year -- in June and July -- for its drug Glimekem.
The Camry hybrid sold 466 units in January-April in the region.
The hatchback has been priced strategically at a notch above the Nano and way below the Tata Bolt.
The draft bill allows euthanasia for patients who can take informed decisions; doctors to be protected from liability.
Daiichi alleged that Singh brothers had concealed and misrepresented critical information concerning US Food and Drug Administration and Department of Justice investigations into Ranbaxy
In 2014, Sun Pharma agreed to buy Ranbaxy -- which was then controlled by Daiichi.
Cars like the Land Rover Evoque, endorsed by Victoria Beckham, have more women customers than men.
NHAI to pull plug on Rs 3,000-crore ventures for poor show
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances